Literature DB >> 21308448

Clinical Trial Report: TMC278 (Rilpivirine) Versus Efavirenz as Initial Therapy in Treatment-Naïve, HIV-1-Infected Patients.

Rodger D Macarthur1.   

Abstract

Entities:  

Year:  2011        PMID： 21308448     DOI： 10.1007/s11908-010-0148-6

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN： 1523-3847            Impact factor:   3.725


× No keyword cloud information.
  3 in total

Review 1.  New antiretroviral drugs: a review of the efficacy, safety, pharmacokinetics, and resistance profile of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir.

Authors:  Christine A Hughes; Linda Robinson; Alice Tseng; Rodger D MacArthur
Journal:  Expert Opin Pharmacother       Date:  2009-10       Impact factor: 3.889

2.  Profile of etravirine for the treatment of HIV infection.

Authors:  Alice Tseng; Rodger D Macarthur
Journal:  Ther Clin Risk Manag       Date:  2010-02-02       Impact factor: 2.423

3.  Virologic, immunologic, clinical, safety, and resistance outcomes from a long-term comparison of efavirenz-based versus nevirapine-based antiretroviral regimens as initial therapy in HIV-1-infected persons.

Authors:  Mary van den Berg-Wolf; Katherine Huppler Hullsiek; Grace Peng; Michael J Kozal; Richard M Novak; Li Chen; Lawrence R Crane; Rodger D Macarthur
Journal:  HIV Clin Trials       Date:  2008 Sep-Oct
  3 in total
  3 in total

1.  Subunit-selective mutational analysis and tissue culture evaluations of the interactions of the E138K and M184I mutations in HIV-1 reverse transcriptase.

Authors:  Hong-Tao Xu; Maureen Oliveira; Peter K Quashie; Matthew McCallum; Yingshan Han; Yudong Quan; Bluma G Brenner; Mark A Wainberg
Journal:  J Virol       Date:  2012-05-23       Impact factor: 5.103

2.  Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme processivity associated with the M184I/V mutations.

Authors:  Hong-Tao Xu; Eugene L Asahchop; Maureen Oliveira; Peter K Quashie; Yudong Quan; Bluma G Brenner; Mark A Wainberg
Journal:  J Virol       Date:  2011-08-17       Impact factor: 5.103

3.  Comprehensive model of wild-type and mutant HIV-1 reverse transciptases.

Authors:  Flavio Ballante; Ira Musmuca; Garland R Marshall; Rino Ragno
Journal:  J Comput Aided Mol Des       Date:  2012-07-26       Impact factor: 3.686
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.